who quit "cold turkey," are successful after 1 year (Fiore et aI., 2000) . Nicotine is the addictive substance in cigarettes and is as addictive as cocaine, heroin, and alcohol (Centers for Disease Control and Prevention [CDC], 2004) . When individuals quit cold turkey, the following nicotine withdrawal symptoms often occur: • Anxiety. • Irritability. • Increased appetite. • Sleep disturbances. • Loss of concentration. • Cravings for cigarettes.
Withdrawal symptoms begin after only a few hours, peak at 3 days, and may last months after the last cigarette. Cravings for a cigarette may last for years after one quits smoking. Without addressing the physical addiction to tobacco dependence with treatment, it is very difficult for most clients to successfully remain . abstinent.
FIRST-LINE AGENTS
Assistingthe ready-to-quit smoking client includes recommending medication to help alleviatethe physicalwithdrawal symptoms. There are six firstline agentsavailable (see Table) : • Patch. • Gum. • Lozenge. • Inhaler. • Nasal spray. • Bupropion.
All of the first-line agents double the abstinence rate at 1 year compared to quitting cold turkey. (Fiore et aI., 2000) . Selecting a medication for smoking cessation should be based on clients' smoking history and preference, contraindications to using any of the products, and coexisting health conditions. Discussing the proper use of the medication, length of treatment, and potential side effects before initiating treatment are important.
The total daily dose of nicotine replacement therapy (NRT) delivers approximately half the amount of nicotine as smoking one pack of cigarettes (20 cigarettes) (Henningfield, 1995) . Although nicotine is the addictive substance in cigarette smoke, nicotine delivered by NRT does not contain carcinogens, tar, and carbon monoxide, which have known health risks (Fiore et aI., 2000) . NRT, therefore, provides enough nicotine to prevent withdrawal symptoms, but not enough or in a manner to cause addiction to the NRT. NRT is not available in a tablet form because nicotine is not readily absorbed through this route of administration.
Nicotine Replacement Patches
NRT patches are available overthe-counter and with a prescription in various doses and tapering schedules (see Table) . Advantages to using NRT patches include ease of use and the constant delivery of low doses of nicotine, preventing withdrawal symptoms. To implement, nurses should. initiate patch use on the client's quit smoking day. The patch should be applied first thing in AAOHN JOURNAL Clinical Rounds: NP link the morning and worn the entire day, either 16 or 24 hours depending on the type of patch. One type of patch is not more clinically effective than another. The l6-hour patch avoids the incidence of vivid dreams that sometimes occur when the patch is worn at night. However, the 24-hour patch helps with cravings for the first cigarette in the morning by delivering nicotine throughout the night. It may be removed at night if vivid dreams occur. Rotating a new patch to a different site each day prevents skin irritation from the adhesive. The NRT patches are safe for use in clients with a history of cardiovascular disease and do not cause myocardial infarctions (Joseph et al., 1996; Kimmel et al., 2001) . Smoking with the patch on may cause nicotine toxicity (e.g., nausea, vomiting, headache) and is a sign of inadequate treatment. If the client is still craving cigarettes while using the patch, the nurse may review coping strategies, as discussed in Part II of this series (Berry, 2005) , and possibly supplement with additional NRT.
Nicoline Replacement Gum and Lozenge
NRT gum and lozenges have very similar delivery mechanisms and allow the client to have more control. Nicotine is released by chewing the gum or sucking the lozenge. The gum or lozenge is then placed in the cheek and nicotine is absorbed through the inner lining of the mouth. Repetition of the "chew and park" method after the tingling in the cheek disappears is important for effective dosing (Table) . Using scheduled doses throughout the day helps prevent nicotine withdrawal and failure of these products. Drinking and eating while using the gum or the lozenge can decrease the absorption of the nicotine from these products. Dosing of the lozenge is based on the timing of the first cigarette in the morning, whereas the gum is dosed on the number of cigarettes smoked. NRT gum has been shown to ward off unwanted weight gain after smoking cessation while using the product (Danielsson, Rossner, & Westin, 1999 Clinical Rounds: NP link recommended to suggest the flavored NRT gum over the original gum because of the "peppery" or "ash tray" taste of the original NRT gum.
NIcotine Replacement Inhaler and

Nasal Spray
Both the NRT inhaler and nasal spray are available only by prescription. The inhaler looks like a cigarette filter with a mouthpiece that splits open to encase a cartridge containing liquid nicotine. After the cartridge is punctured, the client puffs on the mouthpiece to deliver a vapor of nicotine to the inside cheek for absorption. The inhaler has a menthol flavor, so clients who do not smoke menthol cigarettes may not like the taste of the inhaler.
The NRT nasal spray delivers nicotine to the nasal mucosal lining where it is quickly absorbed. It is a useful product in highly nicotine dependent clients because of the rapid absorption (Sutherland et al., 1992) . The NRT nasal spray has the highest addiction potential of all the NRT products with 15% to 20% of the clients using the spray longer than recommended, and 5% using higher than recommended doses (Fiore et al., 2000) . There is also a high incidence of burning in the nasal passage and throat, which improves with continued use. With both the NRT inhaler and nasal spray, regular use is recommended to avoid withdrawal symptoms.
Bupropion SR
Sustained-release bupropion (bupropion SR) is an antidepressant medication found to help both depressed and non-depressed clients stop smoking. The exact mechanism of action is not known, but it is thought to work in the reward center of the brain, the same area nicotine works, alleviating nicotine withdrawal. When bupropion SR works, the client often thinks cigarettes start to "taste bad." Smoking is permissible for the first 1 to 2 weeks after initiating bupropion SR because it does not contain nicotine and it takes time to achieve therapeutic levels.
Insomnia, dry mouth, and dizziness are the most common side ef-fects of taking bupropion SR. It is recommended to start the medication slowly and avoid taking it at bedtime to decrease insomnia. Bupropion SR is contraindicated in clients with a current or previous history of seizures, anorexia nervosa, bulimia, head trauma, or any condition or current medication that may cause seizures. The incidence of seizures with bupropion SR is dose-related (l in 1,000 with doses up to 300 mg daily). One beneficial side effect of this medication is weight loss. Weight gain after smoking cessation was avoided while receiving bupropion SR (Jain et al., 2002) . Bupropion SR is not addictive and does not need a dosing taper with discontinuation.
PRECAUTIONS
Precautions should be exercised when using NRT in individuals with uncontrolled arrhythmias, those with serious or worsening chest pain, and those with a recent (within 2 weeks) myocardial infarction. Nicotine in NRT may worsen these conditions; however, the risks of NRT are small compared to the risks if the individuals continue to smoke.
Because smoking is so harmful to fetuses, pregnant clients who smoke should be treated for smoking cessation. It is currently recommended that pregnant clients who are ready to quit smoking first attempt to quit using behavioral modifications (Fiore et al., 2000) . Intermittent use of NRT (i.e., lozenge, gum, nasal spray, inhaler) or bupropion SR may be an option for pregnant clients unable to quit with behavioral treatment alone (Benowitz & Dempsey, 2004) .
COMBINATION THERAPY
Using more than one medication to assist clients with their quit attempt may be necessary in certain situations, although combination therapy is not FDA approved. Clients who fail using monotherapy because they experience continuous cravings or smoke more than one pack of cigarettes each day may need combination therapy. Combinations studied have all included the nicotine replacement patches, delivering continuous nicotine and "as needed" medications, such as the gum or inhaler to help with the oral or handling fixations. The combination of the NRT patch and bupropion SR had better abstinence rates at 1 year compared to placebo or the NRT patch alone, but not bupropion SR alone (Jorenby et aI., 1999) .
SECOND-LINE AGENTS
Clonidine and nortriptyline are available as second-line treatments for tobacco dependence. Clonidine is a medication for hypertension that has been used to treat alcohol and heroin withdrawal symptoms. Oral and transdermal clonidine have been studied for nicotine withdrawal and found to be effective; however, the high incidence of side effects such as dry mouth, sedation, and constipation limit its use (Hilleman, Mohiuddin, Delcore, & Lucas, 1993) . Nortriptyline, an antidepressant, has been studied and shown to be effective for smoking cessation (da Costa, Younes, & Cruz-Lorenco, 2002) . Dry mouth, constipation, and headache limit compliance with this medication and, clinically, it remains a second-line treatment.
INVESTIGATIONAL TREATMENTS
Rimonabant (Sanofi-Aventis) and varenicline (Pfizer) are two therapeutic agents in preliminary clinical trials. Rimonabant is an oral medication in a new class known as the cannabinoid CB1receptor antagonists. By blocking this receptor in the brain, the rewarding effects of nicotine are diminished (Le FoIl & Goldberg, 2004) . Dosed at 20 mg daily, rimonabant use has doubled abstinence rates in short-term trials (Kimmon, 2004) . Rimonabant is also being studied for its weight and lipid lowering effects. Varenicline is a nicotinic receptor partial agonist thought to relieve nicotine cravings and withdrawal and to block the rewarding effects of smoking cigarettes. Continuous quit rates at 4 weeks more than doubled when varenicline 1 mg was administered orally twice daily compared to placebo (Oncken, Watsky, Reeves, & Anziano, 2005) . Nausea is the limiting side effect associated with varenicline.
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Clinical Rounds: NP link CONCLUSION Effective therapies for treating tobacco dependence are available with and without a prescription. Every health care provider needs to take responsibility and do the following: • Ask all clients if they use tobacco products.
• Advise clients to stop smoking. • Assess clients' willingness to quit smoking. • Assist clients with the quit attempt by recommending first-line smoking cessation medications. • Arrange follow up so clients may receive continued motivation and support.
Occupational health professionals can assist clients through various interventions, including wellness programs and individual counseling sessions. Until health care professionals begin to recognize tobacco dependence as a chronic illness and treat this illness with effective medications, smoking will continue to be the greatest single cause of morbidity and mortality in the United States.
